Mr Moiad Alazzam

MD, MRCOG


  • Specialities Gynaecology, Women's Health
  • Year of first qualification 1997
  • Email
  • Languages spoken

    English, Arabic

  • GMC Number 5209256

Profile

Mr Alazzam is a dual accredited consultant gynaecological surgeon and gynae-oncology subspecialist. His NHS base is Oxford University Hospitals. He is a recognised expert in complex gynaecological surgery both open and minimally invasive; laparoscopy, robotics and hysteroscopic surgery. In addition to oncology, Mr Alazzam is a recognised expert in endometriosis treatment and reconstructive pelvic surgery. He is regularly invited to speak at national and international conferences in the subject. Mr Alazzam is actively involved in research and is widely published. His main areas of interest are health innovation with particular focus on patient-centred care and fertility preservation surgical techniques.

Mr Alazzam’s expertise in diagnostic procedures such as colposcopy and hysteroscopy coupled with his expertise in complex gynaecological surgery allows him to provide comprehensive, high quality care to women presenting with a wide range of gynaecological problems. 

Zoe, his PA, is a great asset to his practice. She is kind, passionate, flexible, accommodating and always go over and beyond to make each patient feel special and well looked after.


Clinics

  • Monday & Tuesday Evening 18:00 - 20:00
  • Friday Morning

Locations

Current posts

  • Oxford University Hospitals NHS Trust

Interests

  • Colposcopy
  • Cancer surgery
  • Fertility preservation surgery
  • Endometriosis
  • Complex laparoscopy & hysteroscopy surgery
  • Menstrual problems
  • Cosmetic gynaecology
  • Pelvic floor surgery
  • Ovarian cysts and fibroids

Other interests

Health Innovation and Technology. Co Founder of “MyData App”: A block-chain powered Patient-Centred Health Information Exchange Platform


Personal interests

  • Enjoying spare time with family
  • Sports & keeping fit

Member of

  • Royal College of Obstetricians & Gynaecologists
  • British Society of Gynaecological Endoscopy
  • British Society of Colposcopy & Cervical Pathology
  • European Society of Gynaecological Oncology
  • European Society of Surgical Oncology
  • American Association of Laparoscopic Gynaecological Surgeons

Research

Tranoulis A, Georgiou D, Alazzam M, Borley J. Combined laparoscopic uterine artery occlusion and myomectomy versus laparoscopic myomectomy: A direct comparison meta-analysis of short and long term outcomes in women with symptomatic leiomyomas. J Minim Invasive Gynecol. 2019 Feb 15. S1553-4650(19) 30090-1.doi:10.1016/j.jmig.2019.02.004[Epub ahead of print]. PMID: 30776497

Lawrie TA, Alazzam M, Tidy J, Hancock BW, Osborne R. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2016 Jun 9;(6):CD007102. doi: 10.1002/14651858.CD007102.pub4. Review. PMID: 27281496

ID Gallos, M Alazzam, TJ Clark, R Faraj, AN Rosenthal, PP Smith, JK Gupta. Management of Endometrial Hyperplasia. RCOG Green-top Guideline No.67. February 2016

Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, Lawrie TA. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2016 Jan 13;1:CD008891. doi: 10.1002/14651858.CD008891.pub3. Review. PMID: 26760424

Jones GL, Jacques RM, Thompson J, Wood HJ, Hughes J, Ledger W, Alazzam M, Radley SC, Tidy JA. The impact of surgery for vulval cancer upon health-related quality of life and pelvic floor outcomes during the first year of treatment: a longitudinal, mixed methods study. Psychooncology. 2015 Sep 25. doi: 10.1002/pon.3992. [Epub ahead of print] PMID: 26403828

Bowes H, Jones G, Thomson J, Alazzam M, Wood H, Hinchliff S, Ledger W, Tidy J. Understanding the impact of the treatment pathway upon health-related quality of life in women with newly diagnosed endometrial cancer – qualitative study. Eur J Oncol Nurs. 2013 Nov 27. [Epub ahead of  print]. PMID:24290535.

Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, Lawrie TA. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia . Cochrane Database Systematic Review. 2012 Dec 12; 12: CD008891.  PMID: 23235667

Alazzam M, Tidy J, Hancock BW, Osborne R, Lawrie TA. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2012 Jul11; 7:CD007102. PMID: 22786502

Alazzam M, Gillespie A, Hewitt M. Robotic surgery in the management of cervical carcinoma. Arch Gynecol Obstet. 2011 Oct ; 284 (4): 937-43. PMID: 21750921

Alazzam M, Young T, Coleman R, Hancock B, Drew D, Wilson P, Tidy J. Predicting gestational trophoblastic neoplasia (GTN): Is urine hCG the answer? Gynecol Oncol. 2011 Sep; 122(3): 595-9. PMID: 21684585

Alazzam M, Tidy J, Hancock BW, Powers HJ. Gestational Trophoblastic Neoplasia, an Ancient Disease: New Light and Potential Therapeutic Targets. Anticancer Agents Med Chem. 2010; 10(2): 176-85.  PMID: 20015010

Alazzam M, Patterson A, Shafi M. Histologic and colposcopic correlation of cervical cytology showing "? glandular neoplasia". Arch Gynecol Obstet. 2010; 281(4): 703-7. PMID: 19774389.

Alazzam M, Tidy J, Hancock BW, Osborne R. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2009 Jan 21; (1):CD007102. PMID:19160319.

Dhulkotia JS, Alazzam M, Galimberti A. Tisseel for management of traumatic postpartum haemorrhage. Arch Gynecol Obstet. 2009; 279(3):437-9. PMID: 18985368.

Alazzam M, Hancock BW, Tidy J. Role of Hysterectomy in Managing Persistent Gestational Trophoblastic Disease. J Reprod Med 2008; 53: 519-24.

Book Chapter:

Alazzam M and Hancock BW. Gestational trophoblastic disease (GTD); Oxford Desk Reference - Oncology (Eds. T Ajithkumar, N Cook, H Hatcher, A Barrett, M Aapro) ISBN 9780199235636. 

Declaration

Mr Moiad Alazzam works with the following private medical insurance providers:
  • Aviva Health
  • AXA PPP Healthcare
  • AXA PPP International
  • Cigna
  • Vitality Health (Pru Health)

Mr Moiad Alazzam does not hold a share or financial interest in this hospital, another Nuffield Health hospital or the company.

Mr Moiad Alazzam does not have a share or financial interest in equipment used at this hospital or another Nuffield Health hospital.

Mr Moiad Alazzam does not hold any paid advisory role(s) at this hospital or on behalf of Nuffield Health.